Neuer Start, neuer Risk!!! (Seite 5)
eröffnet am 14.05.16 01:52:48 von
neuester Beitrag 18.08.22 14:24:11 von
neuester Beitrag 18.08.22 14:24:11 von
Beiträge: 100
ID: 1.231.746
ID: 1.231.746
Aufrufe heute: 0
Gesamt: 12.452
Gesamt: 12.452
Aktive User: 0
ISIN: US72941H5090 · WKN: A3EEZB · Symbol: XMP0
2,0350
EUR
-0,25 %
-0,0050 EUR
Letzter Kurs 17.05.24 Tradegate
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,0000 | +6.045,74 | |
| 0,8600 | +36,51 | |
| 0,8600 | +17,95 | |
| 1,2900 | +12,17 | |
| 2,0600 | +11,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9080 | -14,82 | |
| 3,0100 | -17,31 | |
| 0,6000 | -18,92 | |
| 1,4500 | -21,62 | |
| 3,5800 | -24,79 |
Beitrag zu dieser Diskussion schreiben
Feedback
Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study
Jun 28, 2018
BARDA Funded Study Published in the Journal “Burns”
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial.
In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft. All animals received skin grafting procedures, burn dressings, and other supportive care commonly used in burn centers around the USA.
No serious adverse events related to ADRC infusion were noted in any of the animals. Delivery of ADRCs appeared to be safe with none of the systemic safety parameters worsened compared to the control group. Importantly, skin graft healing was significantly faster in ADRC-treated animals such that five days after treatment wounds in animals treated with ADRCs were 27.1±11.8% epithelialized compared to only 1.1±1.1% in control animals (p<0.05). Skin barrier function (ability to prevent water loss) was 20-fold greater in ADRC-treated wounds than in controls on Day 9 after treatment (32.8±6.3 vs. 157.8±57.3 g/m2/h, respectively; p=0.01). Skin biological elasticity was also significantly greater in ADRCs-treated animals compared to those treated with LR (0.50±0.1 vs. 0.44± 0.02, respectively; p=0.017). Similar improvement in healing was also evident in donor sites (epithelialization 52.8% vs. 33.1% on Day 5 post-treatment) and partial thickness burn (epithelialization 81.8% vs. 59.8% on Day 18 post-treatment).
Overall, the results of this study showed that healing of skin grafts occurred more rapidly in ADRC-treated animals than in controls with more rapid formation of new skin (epithelialization), earlier restoration of skin function (ability to resist water evaporation), and improved skin elasticity.
The paper entitled “Preclinical Assessment of Safety and Efficacy of Intravenous Delivery of Autologous Adipose-Derived Regenerative Cells (ADRCs) in the Treatment of Severe Thermal Burns using a Porcine Model” was published today in the journal Burns and is now available online.
The findings from this preclinical study have been incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial is designed to assess Cytori Cell Therapy in human patients with substantial thermal burn injury using several of the end points used in this preclinical study including epithelialization, skin barrier function, and skin elasticity.
“Healing of meshed skin grafts remains an important clinical problem in burn care,” said Dr. John Fraser, Chief Scientist at Cytori. “We look forward to adding to the number of clinical sites already recruiting patients for the RELIEF trial and to assessing clinical data from RELIEF which applies the same treatment approach to treat very similar wounds.”
The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from slow healing, pain, scarring, skin contracture and reduced range of motion.
Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the U.S. Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.
About RELIEF
The RELIEF trial is designed to assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft. Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial is also designed to assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 15 patients in up to 10 U.S. sites. The trial has been initiated at two sites. Cytori anticipates adding additional sites at a cadence of approximately one per month.
http://ir.cytori.com/investor-relations/news/news-details/20…
Jun 28, 2018
BARDA Funded Study Published in the Journal “Burns”
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial.
In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft. All animals received skin grafting procedures, burn dressings, and other supportive care commonly used in burn centers around the USA.
No serious adverse events related to ADRC infusion were noted in any of the animals. Delivery of ADRCs appeared to be safe with none of the systemic safety parameters worsened compared to the control group. Importantly, skin graft healing was significantly faster in ADRC-treated animals such that five days after treatment wounds in animals treated with ADRCs were 27.1±11.8% epithelialized compared to only 1.1±1.1% in control animals (p<0.05). Skin barrier function (ability to prevent water loss) was 20-fold greater in ADRC-treated wounds than in controls on Day 9 after treatment (32.8±6.3 vs. 157.8±57.3 g/m2/h, respectively; p=0.01). Skin biological elasticity was also significantly greater in ADRCs-treated animals compared to those treated with LR (0.50±0.1 vs. 0.44± 0.02, respectively; p=0.017). Similar improvement in healing was also evident in donor sites (epithelialization 52.8% vs. 33.1% on Day 5 post-treatment) and partial thickness burn (epithelialization 81.8% vs. 59.8% on Day 18 post-treatment).
Overall, the results of this study showed that healing of skin grafts occurred more rapidly in ADRC-treated animals than in controls with more rapid formation of new skin (epithelialization), earlier restoration of skin function (ability to resist water evaporation), and improved skin elasticity.
The paper entitled “Preclinical Assessment of Safety and Efficacy of Intravenous Delivery of Autologous Adipose-Derived Regenerative Cells (ADRCs) in the Treatment of Severe Thermal Burns using a Porcine Model” was published today in the journal Burns and is now available online.
The findings from this preclinical study have been incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial is designed to assess Cytori Cell Therapy in human patients with substantial thermal burn injury using several of the end points used in this preclinical study including epithelialization, skin barrier function, and skin elasticity.
“Healing of meshed skin grafts remains an important clinical problem in burn care,” said Dr. John Fraser, Chief Scientist at Cytori. “We look forward to adding to the number of clinical sites already recruiting patients for the RELIEF trial and to assessing clinical data from RELIEF which applies the same treatment approach to treat very similar wounds.”
The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from slow healing, pain, scarring, skin contracture and reduced range of motion.
Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the U.S. Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.
About RELIEF
The RELIEF trial is designed to assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft. Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial is also designed to assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 15 patients in up to 10 U.S. sites. The trial has been initiated at two sites. Cytori anticipates adding additional sites at a cadence of approximately one per month.
http://ir.cytori.com/investor-relations/news/news-details/20…
Cytori details subscription rights offering
Jun. 12, 2018 9:31 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
Cytori Therapeutics (CYTX) advises investors to buy shares by Friday, June 22, in order to quality for its planned rights offering.
Shareholders of record on that date will receive one non-transferable subscription right for each common share or Series B Convertible Preferred share held.
Each right will entitle the holder to purchase one unit at $1,000 per unit, each consisting of one share of Series C Convertible Preferred Stock and 200 warrants to purchase Cytori common stock at $3.17 per share. Each Series C share, with a face value of $1,000, will be immediately convertible into common shares at $2.64.
The rights may be exercised until 5:00 pm ET on Friday, July 13, unless extended by the company.
https://seekingalpha.com/news/3363289-cytori-details-subscri…
Jun. 12, 2018 9:31 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
Cytori Therapeutics (CYTX) advises investors to buy shares by Friday, June 22, in order to quality for its planned rights offering.
Shareholders of record on that date will receive one non-transferable subscription right for each common share or Series B Convertible Preferred share held.
Each right will entitle the holder to purchase one unit at $1,000 per unit, each consisting of one share of Series C Convertible Preferred Stock and 200 warrants to purchase Cytori common stock at $3.17 per share. Each Series C share, with a face value of $1,000, will be immediately convertible into common shares at $2.64.
The rights may be exercised until 5:00 pm ET on Friday, July 13, unless extended by the company.
https://seekingalpha.com/news/3363289-cytori-details-subscri…
Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?
Dane Simmons
Simply Wall St.May 26, 2018
Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. The US$16.16M market-cap company’s loss lessens since it announced a -US$26.66M bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$23.53M, as it approaches breakeven. As path to profitability is the topic on CYTX’s investors mind, I’ve decided to gauge market sentiment. In this article, I will touch on the expectations for CYTX’s growth and when analysts expect the company to become profitable.
CYTX is bordering on breakeven, according to analysts. They expect the company to post a final loss in 2019, before turning a profit of US$25.48M in 2020. CYTX is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, I calculated the rate at which CYTX must grow year-on-year. It turns out an average annual growth rate of 72.13% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, CYTX may become profitable much later than analysts predict.
I’m not going to go through company-specific developments for CYTX given that this is a high-level summary, though, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Before I wrap up, there’s one issue worth mentioning. CYTX currently has a debt-to-equity ratio of 161.90%. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, and CYTX has considerably exceeded this. Note that a higher debt obligation increases the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of CYTX to cover in one brief article, but the key fundamentals for the company can all be found in one place – CYTX’s company page on Simply Wall St. I’ve also put together a list of important aspects you should further examine:
Valuation: What is CYTX worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CYTX is currently mispriced by the market.
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cytori Therapeutics’s board and the CEO’s back ground.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
https://finance.yahoo.com/news/cytori-therapeutics-inc-nasda…
Dane Simmons
Simply Wall St.May 26, 2018
Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. The US$16.16M market-cap company’s loss lessens since it announced a -US$26.66M bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$23.53M, as it approaches breakeven. As path to profitability is the topic on CYTX’s investors mind, I’ve decided to gauge market sentiment. In this article, I will touch on the expectations for CYTX’s growth and when analysts expect the company to become profitable.
CYTX is bordering on breakeven, according to analysts. They expect the company to post a final loss in 2019, before turning a profit of US$25.48M in 2020. CYTX is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, I calculated the rate at which CYTX must grow year-on-year. It turns out an average annual growth rate of 72.13% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, CYTX may become profitable much later than analysts predict.
I’m not going to go through company-specific developments for CYTX given that this is a high-level summary, though, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Before I wrap up, there’s one issue worth mentioning. CYTX currently has a debt-to-equity ratio of 161.90%. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, and CYTX has considerably exceeded this. Note that a higher debt obligation increases the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of CYTX to cover in one brief article, but the key fundamentals for the company can all be found in one place – CYTX’s company page on Simply Wall St. I’ve also put together a list of important aspects you should further examine:
Valuation: What is CYTX worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CYTX is currently mispriced by the market.
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cytori Therapeutics’s board and the CEO’s back ground.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
https://finance.yahoo.com/news/cytori-therapeutics-inc-nasda…
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
Apr 30, 2018
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918 has been designed and developed to be bioequivalent to the market leading branded reference drug, Caelyx/Doxil (Johnson & Johnson).
Liposomal doxorubicin is a commonly used cytotoxic agent for recurrent breast and ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The global market is anticipated to grow to $1.4B by 2024 (Grand View Research, Inc., 28 2nd Street, Suite 3036, San Francisco, CA, 94105, United States).
Cytori intends to first seek European approval for its drug and has applied for and has received EMA approval to file for centralized European Union (EU) approval. Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body. Approval by EMA using a centralized procedure leads to approval of the product in all 28 EU Member States, Iceland, Liechtenstein and Norway.
All states of manufacturing of the product will be performed in the United States. More specifically, manufacturing of the cytotoxic liposomal formulation will be performed in Cytori’s San Antonio Texas facility. Cytori’s facility features a new manufacturing clean room and technology specifically designed for the manufacture of complex liposomal compounds integrating cytotoxic compounds. In addition, Cytori has in house analytical chemistry capabilities to ensure its products are manufactured to the highest quality standards.
Final sterile packaging and fill finish activities will also be performed in the United States by Bryllan, located in Brighton, Michigan. Bryllan is a premier commercial scale contract manufacturing organization capable of safely filling potent and cytotoxic compounds, hormones, antibodies and complex biologics, live viruses and vaccines. Bryllan features a state-of-the-art aseptic production facility using isolators as the core technology with the highest engineering standards of design and construction to meet US FDA and other global regulatory standards.
http://ir.cytori.com/investor-relations/news/news-details/20…
Apr 30, 2018
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918 has been designed and developed to be bioequivalent to the market leading branded reference drug, Caelyx/Doxil (Johnson & Johnson).
Liposomal doxorubicin is a commonly used cytotoxic agent for recurrent breast and ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The global market is anticipated to grow to $1.4B by 2024 (Grand View Research, Inc., 28 2nd Street, Suite 3036, San Francisco, CA, 94105, United States).
Cytori intends to first seek European approval for its drug and has applied for and has received EMA approval to file for centralized European Union (EU) approval. Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body. Approval by EMA using a centralized procedure leads to approval of the product in all 28 EU Member States, Iceland, Liechtenstein and Norway.
All states of manufacturing of the product will be performed in the United States. More specifically, manufacturing of the cytotoxic liposomal formulation will be performed in Cytori’s San Antonio Texas facility. Cytori’s facility features a new manufacturing clean room and technology specifically designed for the manufacture of complex liposomal compounds integrating cytotoxic compounds. In addition, Cytori has in house analytical chemistry capabilities to ensure its products are manufactured to the highest quality standards.
Final sterile packaging and fill finish activities will also be performed in the United States by Bryllan, located in Brighton, Michigan. Bryllan is a premier commercial scale contract manufacturing organization capable of safely filling potent and cytotoxic compounds, hormones, antibodies and complex biologics, live viruses and vaccines. Bryllan features a state-of-the-art aseptic production facility using isolators as the core technology with the highest engineering standards of design and construction to meet US FDA and other global regulatory standards.
http://ir.cytori.com/investor-relations/news/news-details/20…
Trading Spotlight
Cytori readies subscription rights offering
Apr. 28, 2018 11:50 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
Cytori Therapeutics (NASDAQ:CYTX) has filed a prospectus for a subscription rights offering to existing shareholders.
The free-of-charge non-transferable offering will provide for the purchase one Unit for each share owned. Each unit will consist of one share of common stock and one warrant to purchase one share of common. Price, volume and terms have yet to be announced.
https://seekingalpha.com/news/3350070-cytori-readies-subscri…
https://seekingalpha.com/filing/3993332?uprof=45
Apr. 28, 2018 11:50 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
Cytori Therapeutics (NASDAQ:CYTX) has filed a prospectus for a subscription rights offering to existing shareholders.
The free-of-charge non-transferable offering will provide for the purchase one Unit for each share owned. Each unit will consist of one share of common stock and one warrant to purchase one share of common. Price, volume and terms have yet to be announced.
https://seekingalpha.com/news/3350070-cytori-readies-subscri…
https://seekingalpha.com/filing/3993332?uprof=45
War ja richtig anstrengend heir, kaufen, verkaufen, die 2 Spruenge gut mitgemacht im Januar.
Hoffe das es wieder runtergeht, damit ich nochmals einkaufen kann. Hab alles raus letzte Woche.
Cytori ist for mich ein richtiger Shortstock.
Hoffe das es wieder runtergeht, damit ich nochmals einkaufen kann. Hab alles raus letzte Woche.
Cytori ist for mich ein richtiger Shortstock.
Von Ariva.de, user warkla2 geliehen:
Corey Williams - 5. Januar 2018, 17:20 Uhr EDT Teilen auf:
Cytori Therapeutics Inc (NASDAQ: CYTX ) war heute der Bullenmarkt der Wall Street mit Aktien, die 74% flogen.
Die Ursache all der begeisterten Aufregung? Der japanische Pharmariese Takeda Pharmaceutical beabsichtigt, TiGenix, ein fortschrittliches biopharmazeutisches Unternehmen, das neue Stammzelltherapien für ernsthafte Erkrankungen entwickelt, zu einem Kaufpreis von 1,78 Euro pro Aktie zu erwerben. Dies entspricht einem Transaktionswert von rund 520 Millionen Euro auf vollständig verwässerter Basis. Investoren sehen in der Akquisition von Tigenix ein positives "Interesse" -Signal für den Bereich der regenerativen Medizin und speziell für Cytori, das ein ähnliches Produkt auf Fettbasis hat.
Gruß
Corey Williams - 5. Januar 2018, 17:20 Uhr EDT Teilen auf:
Cytori Therapeutics Inc (NASDAQ: CYTX ) war heute der Bullenmarkt der Wall Street mit Aktien, die 74% flogen.
Die Ursache all der begeisterten Aufregung? Der japanische Pharmariese Takeda Pharmaceutical beabsichtigt, TiGenix, ein fortschrittliches biopharmazeutisches Unternehmen, das neue Stammzelltherapien für ernsthafte Erkrankungen entwickelt, zu einem Kaufpreis von 1,78 Euro pro Aktie zu erwerben. Dies entspricht einem Transaktionswert von rund 520 Millionen Euro auf vollständig verwässerter Basis. Investoren sehen in der Akquisition von Tigenix ein positives "Interesse" -Signal für den Bereich der regenerativen Medizin und speziell für Cytori, das ein ähnliches Produkt auf Fettbasis hat.
Gruß
Cytori Therapeutics jumps as Maxim sees it as takeover candidate
Jan. 5, 2018 6:42 PM ET|About: Cytori Therapeutics Inc (CYTX)|By: Jason Aycock, SA News Editor
•Nanocap Cytori Therapeutics (NASDAQ:CYTX) vaulted in the last 15 minutes of the week's trading to a 74% gain after it was floated as a likely acquisition candidate by Maxim.
•Analyst Jason Kolbert sees Takeda's (OTCPK:TKPYY) play for Tigenix (NASDAQ:TIG) as a positive sign for Cytori, since it makes a similar adipose-based product for regenerative medicine.
•He has a price target of $5 vs. today's close of $0.47.
•Volume was about 7.7M shares today vs. an average of less than 1M. Shares have drawn back slightly postmarket, -13%.
•Source: Bloomberg
https://seekingalpha.com/news/3321520-cytori-therapeutics-ju…
Jan. 5, 2018 6:42 PM ET|About: Cytori Therapeutics Inc (CYTX)|By: Jason Aycock, SA News Editor
•Nanocap Cytori Therapeutics (NASDAQ:CYTX) vaulted in the last 15 minutes of the week's trading to a 74% gain after it was floated as a likely acquisition candidate by Maxim.
•Analyst Jason Kolbert sees Takeda's (OTCPK:TKPYY) play for Tigenix (NASDAQ:TIG) as a positive sign for Cytori, since it makes a similar adipose-based product for regenerative medicine.
•He has a price target of $5 vs. today's close of $0.47.
•Volume was about 7.7M shares today vs. an average of less than 1M. Shares have drawn back slightly postmarket, -13%.
•Source: Bloomberg
https://seekingalpha.com/news/3321520-cytori-therapeutics-ju…
Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today
Corey Williams-January 5, 2018, 5:20 PM EDT
Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street’s bull of the day today with shares that flew 74%.
The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive “interest” signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.
On the ratings front, Cytori has been the subject of a number of recent research reports. In a report released today, Maxim analyst Jason Kolbert assigned a Buy rating on CYTX, with a price target of $5.00, which represents a potential upside of 1752% from where the stock is currently trading. On November 10, B.Riley FBR’s Andrew D’silva maintained a Hold rating on the stock and has a price target of $0.50.
https://www.smarteranalyst.com/2018/01/05/heres-cytori-thera…
Corey Williams-January 5, 2018, 5:20 PM EDT
Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street’s bull of the day today with shares that flew 74%.
The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive “interest” signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.
On the ratings front, Cytori has been the subject of a number of recent research reports. In a report released today, Maxim analyst Jason Kolbert assigned a Buy rating on CYTX, with a price target of $5.00, which represents a potential upside of 1752% from where the stock is currently trading. On November 10, B.Riley FBR’s Andrew D’silva maintained a Hold rating on the stock and has a price target of $0.50.
https://www.smarteranalyst.com/2018/01/05/heres-cytori-thera…
Durchsuchen
